Press Release: Revvity to Hold Earnings Call on Monday, April 28, 2025

Dow Jones

04-03

Revvity to Hold Earnings Call on Monday, April 28, 2025

WALTHAM, Mass.--(BUSINESS WIRE)--April 03, 2025--

Revvity, Inc. $(RVTY)$, today announced that it will release its first quarter 2025 financial results prior to market open on Monday, April 28, 2025. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call.

To access the call, a live audio webcast will be available on the Investors section of the Company's website.

About Revvity

At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

With 2024 revenue of more than $2.7 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 160 countries.

Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250403142939/en/

 
    CONTACT:    Investor Relations:

Steve Willoughby

steve.willoughby@revvity.com

Revvity Media Relations:

Chet Murray

(781) 462-5126

chet.murray@revvity.com

(END) Dow Jones Newswires

April 03, 2025 08:04 ET (12:04 GMT)

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2524225634"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2524225634\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2524225634?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-03 20:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2524225634","market":"hk","top_or_hot":-1,"title":"Press Release: Revvity to Hold Earnings Call on Monday, April 28, 2025","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  Revvity to Hold Earnings Call on Monday, April 28, 2025 \n</p>\n<pre>\nWALTHAM, Mass.--(BUSINESS WIRE)--April 03, 2025-- \n</pre>\n<p>\n     Revvity, Inc. <a href=\"https://laohu8.com/S/RVTY\">$(RVTY)$</a>, today announced that it will release its first quarter 2025 financial results prior to market open on Monday, April 28, 2025. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. \n</p>\n<p>\n     To access the call, a live audio webcast will be available on the Investors section of the Company's website. \n</p>\n<p>\n     About Revvity \n</p>\n<p>\n     At Revvity, \"impossible\" is inspiration, and \"can't be done\" is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. \n</p>\n<p>\n     With 2024 revenue of more than $2.7 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&amp;P 500 index and has customers in more than 160 countries. \n</p>\n<p>\n     Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram. \n</p>\n<p>\n     View source version on businesswire.com: https://www.businesswire.com/news/home/20250403142939/en/ \n</p>\n<pre>\n \n    CONTACT:    Investor Relations: \n</pre>\n<p>\n     Steve Willoughby \n</p>\n<p>\n     steve.willoughby@revvity.com \n</p>\n<p>\n     Revvity Media Relations: \n</p>\n<p>\n     Chet Murray \n</p>\n<p>\n     (781) 462-5126 \n</p>\n<p>\n     chet.murray@revvity.com \n</p>\n<pre>\n \n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 03, 2025 08:04 ET (12:04 GMT)\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Press Release: Revvity to Hold Earnings Call on Monday, April 28, 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPress Release: Revvity to Hold Earnings Call on Monday, April 28, 2025\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-04-03 20:04</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  Revvity to Hold Earnings Call on Monday, April 28, 2025 \n</p>\n<pre>\nWALTHAM, Mass.--(BUSINESS WIRE)--April 03, 2025-- \n</pre>\n<p>\n     Revvity, Inc. <a href=\"https://laohu8.com/S/RVTY\">$(RVTY)$</a>, today announced that it will release its first quarter 2025 financial results prior to market open on Monday, April 28, 2025. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. \n</p>\n<p>\n     To access the call, a live audio webcast will be available on the Investors section of the Company's website. \n</p>\n<p>\n     About Revvity \n</p>\n<p>\n     At Revvity, \"impossible\" is inspiration, and \"can't be done\" is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. \n</p>\n<p>\n     With 2024 revenue of more than $2.7 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&amp;P 500 index and has customers in more than 160 countries. \n</p>\n<p>\n     Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram. \n</p>\n<p>\n     View source version on businesswire.com: https://www.businesswire.com/news/home/20250403142939/en/ \n</p>\n<pre>\n \n    CONTACT:    Investor Relations: \n</pre>\n<p>\n     Steve Willoughby \n</p>\n<p>\n     steve.willoughby@revvity.com \n</p>\n<p>\n     Revvity Media Relations: \n</p>\n<p>\n     Chet Murray \n</p>\n<p>\n     (781) 462-5126 \n</p>\n<p>\n     chet.murray@revvity.com \n</p>\n<pre>\n \n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 03, 2025 08:04 ET (12:04 GMT)\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RVTY","symbol_name":"REVVITY INC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2524225634","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2524225634","pubTimestamp":1743681840,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Revvity, Inc. , today announced that it will release its first quarter 2025 financial results prior to market open on Monday, April 28, 2025. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call.To access the call, a live audio webcast will be available on the Investors section of the Company's website.At Revvity, \"impossible\" is inspiration, and \"can't be done\" is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.With 2024 revenue of more than $2.7 billion","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"RVTY":"REVVITY INC"},"translate_title":"新闻稿：Revvity将于2025年4月28日星期一举行收益看涨期权","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RVTY":0.9},"content_text":"Revvity to Hold Earnings Call on Monday, April 28, 2025 \n\n\nWALTHAM, Mass.--(BUSINESS WIRE)--April 03, 2025-- \n\n\n     Revvity, Inc. $(RVTY)$, today announced that it will release its first quarter 2025 financial results prior to market open on Monday, April 28, 2025. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. \n\n\n     To access the call, a live audio webcast will be available on the Investors section of the Company's website. \n\n\n     About Revvity \n\n\n     At Revvity, \"impossible\" is inspiration, and \"can't be done\" is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. \n\n\n     With 2024 revenue of more than $2.7 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 160 countries. \n\n\n     Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram. \n\n\n     View source version on businesswire.com: https://www.businesswire.com/news/home/20250403142939/en/ \n\n\n \n    CONTACT:    Investor Relations: \n\n\n     Steve Willoughby \n\n\n     steve.willoughby@revvity.com \n\n\n     Revvity Media Relations: \n\n\n     Chet Murray \n\n\n     (781) 462-5126 \n\n\n     chet.murray@revvity.com \n\n\n \n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 03, 2025 08:04 ET (12:04 GMT)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}